Effective January 20, 2014, CytoDyn Inc. entered into two Project Work Orders (the PWOs) with its principal clinical research organization, Amarex Clinical Research, LLC. The services to be provided under the PWOs are intended to facilitate the Company's plan to expand and accelerate the concurrent evaluation of additional potential treatment applications of its principal product candidate, PRO 140. The CRO has agreed to provide comprehensive clinical trial services in connection with two research studies involving PRO 140 currently under consideration.

The estimated combined cost of the studies totals $9.3 million, of which $5.1 million relates to services to be provided directly by the CRO and the remainder to pass-through costs to be provided by third parties. Each PWO may be terminated by either party at any time upon 30 days' prior written notice, provided the CRO will be entitled to payment for services provided through the date of termination, plus an amount equal to 30% of the remaining contract amount for direct services. The Company paid the CRO a total deposit of approximately $790,000 in December 2013.